ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Cognition Therapeutics Inc

Cognition Therapeutics Inc (CGTX)

0.283
0.003
( 1.07% )

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
0.283
Bid
0.2829
Ask
0.283
Volume
662,631
0.2824 Day's Range 0.3008
0.222301 52 Week Range 3.44
Market Cap
Previous Close
0.28
Open
0.2832
Last Trade
3
@
0.28295
Last Trade Time
14:18:38
Financial Volume
$ 191,476
VWAP
0.288963
Average Volume (3m)
1,161,884
Shares Outstanding
61,993,046
Dividend Yield
-
PE Ratio
-0.51
Earnings Per Share (EPS)
-0.55
Revenue
-
Net Profit
-33.97M

About Cognition Therapeutics Inc

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an o... Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Camden, Delaware, USA
Founded
-
Cognition Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CGTX. The last closing price for Cognition Therapeutics was $0.28. Over the last year, Cognition Therapeutics shares have traded in a share price range of $ 0.222301 to $ 3.44.

Cognition Therapeutics currently has 61,993,046 shares outstanding. The market capitalization of Cognition Therapeutics is $17.36 million. Cognition Therapeutics has a price to earnings ratio (PE ratio) of -0.51.

CGTX Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.033-10.44303797470.3160.3230.287132670.30400541CS
4-0.0426-13.08353808350.32560.360.22230118307660.29893627CS
12-0.187-39.78723404260.470.48990.22230111618840.32412514CS
26-0.867-75.39130434781.151.290.22230141909680.55856621CS
52-1.937-87.25225225232.223.440.22230127104700.60270092CS
156-1.527-84.3646408841.816.26860.22230110300410.82949874CS
260-11.867-97.67078189312.1513.80.2223018519310.94523871CS

CGTX - Frequently Asked Questions (FAQ)

What is the current Cognition Therapeutics share price?
The current share price of Cognition Therapeutics is $ 0.283
How many Cognition Therapeutics shares are in issue?
Cognition Therapeutics has 61,993,046 shares in issue
What is the market cap of Cognition Therapeutics?
The market capitalisation of Cognition Therapeutics is USD 17.36M
What is the 1 year trading range for Cognition Therapeutics share price?
Cognition Therapeutics has traded in the range of $ 0.222301 to $ 3.44 during the past year
What is the PE ratio of Cognition Therapeutics?
The price to earnings ratio of Cognition Therapeutics is -0.51
What is the reporting currency for Cognition Therapeutics?
Cognition Therapeutics reports financial results in USD
What is the latest annual profit for Cognition Therapeutics?
The latest annual profit of Cognition Therapeutics is USD -33.97M
What is the registered address of Cognition Therapeutics?
The registered address for Cognition Therapeutics is 2140 S DUPONT HWY, KENT, CAMDEN, DELAWARE, 19934
What is the Cognition Therapeutics website address?
The website address for Cognition Therapeutics is www.cogrx.com
Which industry sector does Cognition Therapeutics operate in?
Cognition Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
APVOAptevo Therapeutics Inc
$ 6.18
(119.15%)
117.56M
PTLEPTL Ltd
$ 0.3841
(94.09%)
384.2M
KWEKWESST Micro Systems Inc
$ 10.282
(78.51%)
34.8M
MRINMarin Software Incorporated
$ 1.4597
(71.73%)
38.58M
LZMHLZ Technology Holdings Ltd
$ 24.8007
(55.69%)
707.33k
CBIOCrescent Biopharma Inc
$ 14.5491
(-71.54%)
74.09k
PSTVPlus Therapeutics Inc
$ 0.199
(-35.52%)
20.5M
EYENEyenovia Inc
$ 4.57
(-34.43%)
6.48M
BMEABiomea Fusion Inc
$ 1.95
(-32.76%)
7.7M
CONIGraniteShares ETF Trust 2X Short COIN Daily ETF
$ 3.845
(-30.22%)
12.87M
HCTIHealthcare Triangle Inc
$ 0.026
(17.65%)
384.34M
PTLEPTL Ltd
$ 0.3841
(94.09%)
384.2M
GNLNGreenlane Holdings Inc
$ 0.010401
(0.01%)
203.16M
APVOAptevo Therapeutics Inc
$ 6.18
(119.15%)
117.56M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 12.5248
(4.90%)
111.81M

CGTX Discussion

View Posts
glenn1919 glenn1919 2 weeks ago
CGTX................................https://stockcharts.com/h-sc/ui?s=CGTX&p=W&b=5&g=0&id=p86431144783
👍️0
urge2surge urge2surge 3 months ago
Heavy burn rate. Expect a shelf filing. Just my take.
👍️0
glenn1919 glenn1919 4 months ago
cgtx..................................https://stockcharts.com/h-sc/ui?s=cgtx&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 4 months ago
.64 ready to run ...
👍️0
tw0122 tw0122 5 months ago
Dementia setting in at .79 with some volume 
👍️0
glenn1919 glenn1919 6 months ago
cgtx....................https://stockcharts.com/h-sc/ui?s=cgtx&p=W&b=5&g=0&id=p86431144783
👍️0
Timing101 Timing101 6 months ago
$CTGX Major volume today , Closed in the Green , Low Float , Superbowl Mgt Team and Background in Pharm Launch companies. Positive results in Phase 2 Dementia Testing . See Links (I always provide) below.
8-K today , see attached Company overview
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001455365/000110465924129619/tm2431405d1_8k.htm
-
Presentation from 8-K filed today
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001455365/000110465924129619/tm2431405d1_8k.htm
--
Mgt Team see Bio's ( click on pictures)
https://cogrx.com/about-us/management-team/?_gl=1*nfhroy*_ga*MzEwMDgyNjc3LjE3MzQ1NTUyNjc.*_ga_CKK85WMQ6P*MTczNDU1NTI2Ny4xLjEuMTczNDU1NTM0NS4wLjAuMA..
--
PR out on Testing results
https://www.globenewswire.com/news-release/2024/12/18/2998947/0/en/Cognition-Therapeutics-Announces-Positive-Results-in-Phase-2-Study-of-CT1812-in-Dementia-with-Lewy-Bodies.html
👍️ 2
tw0122 tw0122 6 months ago
$1.24 + 172%
👍️0
tw0122 tw0122 6 months ago
CGTX $1.16
👍️0
tw0122 tw0122 6 months ago
$1.08 + 152%
👍️0
tw0122 tw0122 6 months ago
.98 + 115%
👍️0
tw0122 tw0122 6 months ago
.92 + 102%
👍️0
tw0122 tw0122 6 months ago
.84 + 80%
👍️0
tw0122 tw0122 6 months ago
Flip some more .80
👍️0
tw0122 tw0122 6 months ago
.45 cent shares flipping some now .70
👍️ 1
Guzzi62 Guzzi62 7 months ago
Opened a small position here at 0.38
👍 1
glenn1919 glenn1919 7 months ago
CGTX...........................https://stockcharts.com/h-sc/ui?s=CGTX&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 7 months ago
.69 still going 34m float watch .76 resistance probably max gain. But if it breaks it .90 possible 
👍️0
tw0122 tw0122 7 months ago
Flip rest at .5970
👍️0
TrendTrade2016 TrendTrade2016 7 months ago
DILUTE INTO FLUFF NEWS
👍️0
tw0122 tw0122 7 months ago
.58 flipping half from .47 
👍️0
tw0122 tw0122 7 months ago
.53 “We now have evidence that the dramatic reduction of cognitive decline that was sustained over 6 months in patients treated with CT1812 who had lower plasma p-tau217 levels also was associated with improvements in key indicators of brain cell function. This finding gives us confidence that CT1812 is having a disease-modifying effect,” explained Anthony O. Caggiano, MD, PhD, Cognition’s C
👍 1
tw0122 tw0122 7 months ago
.47 . - Dramatic 95% Reduction of Cognitive Decline in CT1812-treated Patients with Lower Plasma p-tau217 Correlated with Improvements in Key Indicators of Alzheimer’s Disease Biology -
👍 2
Imokhopeur Imokhopeur 9 months ago
More attention here is on the way, imo.
👍️0
Imokhopeur Imokhopeur 9 months ago
I’m in
👍️0
Monksdream Monksdream 10 months ago
CGTX new 52. Week low
👍️0
Awl416 Awl416 11 months ago
T1 halt….
👍️0
Monksdream Monksdream 11 months ago
No news
https://ih.advfn.com/markets/nasdaq/premarket
👍️0
Monksdream Monksdream 11 months ago
CGTX under $3
👍️0
Monksdream Monksdream 11 months ago
Whoops, I did it, again
👍️0
Monksdream Monksdream 11 months ago
CGTX under $2
👍️0
dannyzee84 dannyzee84 1 year ago
Great stock. Future is bright. Bags packed.
👍️0
Monksdream Monksdream 1 year ago
CGTX under $2
👍️0
Monksdream Monksdream 1 year ago
CGTX under $2
👍️0
Monksdream Monksdream 1 year ago
CGTX under $2
👍️0
Monksdream Monksdream 2 years ago
CGTX new 52 week low
👍️0
Monksdream Monksdream 2 years ago
CGTX under $2
👍️0
artfulife artfulife 2 years ago
Is that a wild guess or is there some reasoning behind your statement?
👍️0
willlbone willlbone 2 years ago
Time to buy.
👍️0
crudeoil24 crudeoil24 2 years ago
Great! I believe we'll do quite well on share price surge!
👍️ 1
tw0122 tw0122 2 years ago
Already been here for a few weeks …lol. One of my very few longer term hold OTC plays.
Thanks..
👍️0
crudeoil24 crudeoil24 2 years ago
Nice "pop" on FDA phase II news! If you have time, you may want to check out GDVM. Symbol change happening any day. Two hours of reading you'll be buying shares.
👍️0
tw0122 tw0122 2 years ago

The START study is supported by a grant of approximately $81 million for 5 years from the National Institutes of Health’s (NIH) National Institute on Aging (NIA) to accelerate development of new therapies for Alzheimer’s disease.

“The START study and ACTC represent some of the many ways that NIA funds research into novel therapeutics for treating Alzheimer's and related dementias,” stated Laurie Ryan, Ph.D., an NIA clinical research program official.

“We appreciate the continued support of the NIA, which has been an important partner in our work to develop CT1812. Our lead drug candidate is a potentially disease-modifying oral therapeutic for the treatment of Alzheimer's disease and other neurodegenerative conditions,” added Cognition president and CEO, Lisa Ricciardi. “With the NIA's funding, we have been able to complete a series of preclinical and clinical trials, thus advancing our understanding of CT1812 and the role of the sigma-2 (s-2) receptor in Alzheimer’s disease. We look forward to recruiting patients for the START study with our collaboration partners at the ACTC.”

“ACTC aims to accelerate Alzheimer’s drug development, working with academic and industry partners,” said Paul Aisen, M.D., professor of neurology at the University of Southern California and director of the Alzheimer's Therapeutic Research Institute. “The START study is an important component of ACTC efforts. Having an authorized protocol for the START study is a critical step in preparing to open clinical sites for the trial by mid-2023.”

NEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that it has cleared the U.S. Food and Drug Administration comment period and may now proceed with the 540-patient Phase 2 START study of CT1812 in adults with mild cognitive impairment or early Alzheimer’s disease. This randomized placebo-controlled trial will be conducted at approximately 50-to-60 sites in North America including those premier institutions in the Alzheimer's Clinical Trials Consortium (ACTC). CT1812 is an investigational oral small molecule that binds to a receptor on synapses and is designed to prevent the toxic effects of soluble beta amyloid (Aß) oligomers on neurons, which drive the progression of neurodegenerative diseases such as Alzheimer’s disease.


“The initial clinical results observed with CT1812 are encouraging and we look forward to advancing it into the START trial to evaluate its effects in a larger study in people with early Alzheimer’s disease,” said Christopher H. van Dyck, M.D., director of the Yale Alzheimer's Disease Research Center and primary investigator of the START study. “We envision a future with multiple treatment options, to be used alone or in combination according to evidence, to achieve the greatest slowing of Alzheimer's disease progression.”
👍 1
anderson800 anderson800 2 years ago
Chart is looking better all of the time. The 50 day MA is only about 15 cents away from the 200 day and when we get the golden cross that should trigger a lot of buy signals.
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 3 years ago
$CGTX Love the chart..looking for continuation next week..

https://stockcharts.com/c-sc/sc?s=CGTX&p=D&b=5&g=0&i=0&r=1669471320227
👍️ 1
anderson800 anderson800 3 years ago
Hopefully this has seen its low and now is starting a new uptrend. I just grabbed my first 1000 shares today after seeing the CEO added 71,000 shares.
👍️0
turning stone turning stone 3 years ago
Nope but not any major loss.
👍️0
Pedro2004 Pedro2004 3 years ago
Were you able to get-out with a profit today?
👍️0
turning stone turning stone 3 years ago
While the stock is dropping on no relative news it is a good time to think about purchasing more shares. I have been averaging down and would not mind $2.00/share to bring me more in line with what makes me comfortable.
👍️0
turning stone turning stone 3 years ago
As a new investor in CGTX I look forward to new and interesting posts on the board. I am tired of plain B-S from those who get off on seeing there jibber in print.
👍️0

Your Recent History

Delayed Upgrade Clock